Papers/PMID:34863994
The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial.
European journal of pharmacology2022The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
quercetin — decreases serum alkaline phosphatase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Moreover, serum concentration of ALP demonstrated a remarkable decrease in the patients who were taking quercetin in addition to the antiviral drugs (p: 0.002).”
Quoted verbatim from The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial.. - Study
- RCT
- Duration
- 7 days
- Dose
- 500 mg orally twice daily (1000 mg/day) for 7 days
- Population
- 60 adults hospitalized with severe COVID-19, open-label; remdesivir or favipiravir plus vitamin D, zinc, vitamin C, famotidine and dexamethasone given in both arms, quercetin added in the intervention arm
The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial.2022PMID:34863994Permalink